For the Inventor, By the Inventor

Enter assignee name

Lausanne, Switzerland

Asceneuron Sa

USPTO Granted Patents = 19

CIPO Patents = 8

EPO Patents = 7

Forward Citations = 123

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Anna Quattropani (19 out of 58 patents)

Santosh Shripad Kulkarni (19 out of 52 patents)

Awadut Gajendra Giri (17 out of 17 patents)

4. David Malcolm Crowe (4 out of 8 patents)

5. Dawn V Toronto (3 out of 3 patents)

6. Paul Rakesh (3 out of 3 patents)

7. Grant Wishart (2 out of 4 patents)

8. Johannes Nicolaas Koek (1 out of 5 patents)

9. Kathiravan Murugesan (1 out of 1 patent)

10. Joydeep Banerjee (1 out of 1 patent)

11. Robert Hett (1 out of 1 patent)

19 patents: Sort by Forward Citations

1. 12398130 - Acid addition salts of piperazine derivatives (2025-08-26),

2. 12195455 - Succinate and fumarate acid addition salts of piperazine derivatives (2025-01-14),

3. 12187741 - Glycosidase inhibitors (2025-01-07),

4. 12157734 - Sulfoximine glycosidase inhibitors (2024-12-03),

5. 12016852 - Pyrrolidine glycosidase inhibitors (2024-06-25),

6. 11795165 - Tetrahydro-benzoazepine glycosidase inhibitors (2023-10-24),

7. 11731972 - Spiro compounds as glycosidase inhibitors (2023-08-22),

8. 11612599 - Glycosidase inhibitors (2023-03-28),

9. 11591327 - Acid addition salts of piperazine derivatives (2023-02-28),

10. 11458140 - Annulated glycosidase inhibitors (2022-10-04),

11. 11261183 - Sulfoximine glycosidase inhibitors (2022-03-01),

12. 11213525 - Linear glycosidase inhibitors (2022-01-04),

13. 11046712 - Glycosidase inhibitors (2021-06-29),

14. 10995090 - Substituted dihydrobenzofuran glycosidase inhibitors (2021-05-04),

15. 10696668 - Acid addition salts of piperazine derivatives (2020-06-30),

Asceneuron is a clinical-stage biotechnology company dedicated to developing novel, disease-modifying therapeutics for neurodegenerative and psychiatric disorders. Their passion lies in improving the lives of patients suffering from devastating diseases such as Alzheimer's and Parkinson's. Asceneuron's innovative pipeline targets pathological pathways, aiming to slow or halt disease progression and provide much-needed treatment options. With a team of dedicated scientists and clinical experts, Asceneuron is committed to transforming the future of neurodegenerative medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

19 Patents

#19 in Lausanne

#621 in Switzerland

#31,670 in the World

Lausanne, Switzerland

Asceneuron Sa

Forward Citations = 123

16 inventors:

Anna Quattropani (19 out of 58 patents)

Santosh Shripad Kulkarni (19 out of 52 patents)

Awadut Gajendra Giri (17 out of 17 patents)

4. David Malcolm Crowe (4 out of 8 patents)

5. Dawn V Toronto (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…